BioTime announces changes, reorganization of research products business

BioTime announced changes to the organization and management of its research products business. The research products business will be consolidated into a new ESI BIO Division which shall be BioTime’s primary developer, manufacturer and distributor for its growing portfolio of stem-cell-based research products. Jeffrey Janus, BioTime’s vice president of sales and marketing, will lead ESI BIO and has also been appointed as the CEO of BioTime’s Singapore-based subsidiary ES Cell International which will be a part of the ESI BIO Division.